Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages

  Krishnan, Aruna V ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALCITRIOL; CARBOPLATIN; CYCLOOXYGENASE 2; CYTOKINE; DEXAMETHASONE; DOCETAXEL; DOXERCALCIFEROL; ELOCALCITOL; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 5; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARICALCITOL; PLACEBO; PROSTAGLANDIN; ROFECOXIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; UPREGULATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DUAL-SPECIFICITY PHOSPHATASES; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NEOPLASM PROTEINS; NF-KAPPA B; PROSTAGLANDINS; PROSTATIC NEOPLASMS; PROSTATITIS; RECEPTORS, PROSTAGLANDIN;

EID: 77449083534     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0139     Document Type: Review

References (186)

1. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM et al. 2008 Serum vitamin D concentration and prostate cancer risk: a nested case-control study. Journal of the National Cancer Institute 100 796-804.
2. Ahonen MH, Tenkanen L, Teppo L, Hakama M & Tuohimaa P 2000 Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes & Control 11 847-852.
3. Alagbala A, Moser MT, Johnson CS, Trump DL, Posner GH & Foster BA 2005 Prevention of prostate cancer progression with vitamin D compounds in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Fourth annual AACR International Conference on Frontiers in Cancer Prevention Research, Baltimore, MD, USA. p 107.
4. 3 and its analog (QW-1624F2-2) prevent prostate cancer progression. 13th Workshop on Vitamin D, Victoria, BC, Canada. p 95.
5. Ali O, Cohen P & Lee KW 2003 Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Hormone and Metabolic Research 35 726-733.
6. Allavena P, Garlanda C, Borrello MG, Sica A & Mantovani A 2008 Pathways connecting inflammation and cancer. Current Opinion in Genetics & Development 18 3-10.
7. Angelo LS & Kurzrock R 2007 Vascular endothelial growth factor and its relationship to inflammatory mediators. Clinical Cancer Research 13 2825-2830.
8. Antman EM, DeMets D & Loscalzo J 2005 Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 759-770.
9. 3, a less calcemic vitamin D analog. Journal of Cellular Biochemistry 104 1832-1842.
10. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M et al. 2008 Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clinical Cancer Research 14 2437-2443.
11. Badawi AF 2000 The role of prostaglandin synthesis in prostate cancer. BJU International 85 451-462.
12. Balkwill F 2004 Cancer and the chemokine network. Nature Reviews. Cancer 4 540-550.
13. Bamba H, Ota S, Kato A, Adachi A, Itoyama S & Matsuzaki F 1999 High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. International Journal of Cancer 83 470-475.
14. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, DiPaola RS & Abate-Shen C 2006 Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clinical Cancer Research 12 5895-5901.
15. 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27 1883-1893.
16. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27 32-42.
17. Beer TM & Myrthue A 2006 Calcitriol in the treatment of prostate cancer. Anticancer Research 26 2647-2651.
18. Beer TM, Lemmon D, Lowe BA & Henner WD 2003 High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97 1217-1224.
19. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM et al. 2007 Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. Journal of Clinical Oncology 25 669-674.
20. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD et al. 2008 C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112 2377-2383.
21. 3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Molecular Cancer Therapeutics 6 1433-1439.
22. Bernardi RJ, Johnson CS, Modzelewski RA & Trump DL 2002 Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143 2508-2514.
23. Berry W & Eisenberger M 2005 Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 10 (Suppl 3) 30-39.
24. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138 1491-1497.
25. Blutt SE, McDonnell TJ, Polek TC & Weigel NL 2000 Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141 10-17.
26. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al. 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 343 1520-1528.
27. Boyle BJ, Zhao XY, Cohen P & Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. Journal of Urology 165 1319-1324.
28. Breyer RM, Bagdassarian CK, Myers SA & Breyer MD 2001 Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology and Toxicology 41 661-690.
29. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. Journal of Molecular Endocrinology 19 15-27.
30. Catz SD & Johnson JL 2001 Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 7342-7351.
31. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR & Ryan CW 2008 A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU International 102 1601-1606.
32. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor AC, Guillou PJ, Markham AF, Coletta PL et al. 2000 Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. American Journal of Pathology 156 545-553.
33. Chen TC & Holick MF 2003 Vitamin D and prostate cancer prevention and treatment. Trends in Endocrinology and Metabolism 14 423-430.
34. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cell. British Journal of Cancer 82 2000-2006.
35. Chen TC, Wang L, Whitlatch LW, Flanagan JN & Holick MF 2003 Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. Journal of Cellular Biochemistry 88 315-322.
36. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G & Witte JS 2007 COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. British Journal of Cancer 97 557-561.
37. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL & Johnson CS 2009 Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumorderived endothelial cells and tumor angiogenesis in vivo. Cancer Research 69 967-975.
38. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB & Lokeshwar BL 2006 Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. International Journal of Cancer 119 1082-1087.
39. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C & Douvdevani A 2006 Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrology, Dialysis, Transplantation 21 889-897.
40. 3 in macrophages. Journal of Steroid Biochemistry and Molecular Biology 103 558-562.
41. Coussens LM & Werb Z 2002 Inflammation and cancer. Nature 420 860-867.
42. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB et al. 2004 Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. European Journal of Endocrinology 150 591-603.
43. Criswell T, Leskov K, Miyamoto S, Luo G & Boothman DA 2003 Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22 5813-5827.
44. Culig Z, Steiner H, Bartsch G & Hobisch A 2005 Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry 95 497-505.
45. Deeb KK, Trump DL & Johnson CS 2007 Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews. Cancer 7 684-700.
46. De Marzo AM, Marchi VL, Epstein JI & Nelson WG 1999 Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. American Journal of Pathology 155 1985-1992.
47. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB & Nelson WG 2004 Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry 91 459-477.
48. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB & Nelson WG 2007 Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7 256-269.
49. 3 and its analogs: physiologic and therapeutic implications for dendritic cell function. Journal of Biological Chemistry 278 49378-49385.
50. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB & Lipsky PE 1998 Cyclooxygenase in biology and disease. FASEB Journal 12 1063-1073.
51. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH & Carter HB 2001 Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58 411-416.
52. Feldman D, Malloy PJ, Krishnan AV & Balint E 2007 Vitamin D: biology, action and clinical implications. In Osteoporosis, pp 317-382. Eds R Marcus, D Feldman, DA Nelson & CJ Rosen. San Diego: Academic Press.
53. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP & Kreutzer DL 1998 Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51 161-167.
54. Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED & Glode LM 2006 A phase II, trial of dexamethasone, vitamin D, and carboplatin in patients with hormonerefractory prostate cancer. Cancer 107 266-274.
55. Fleet JC 2008 Molecular actions of vitamin D contributing to cancer prevention. Molecular Aspects of Medicine 29 388-396.
56. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 27-31.
57. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R, Chang SS & Byerly S 2009 Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. Journal of Urology 181 2064-2070.
58. Fukuda R, Kelly B & Semenza GL 2003 Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxiainducible factor 1. Cancer Research 63 2330-2334.
59. 3, a natural metabolite of calcitriol. Journal of Steroid Biochemistry and Molecular Biology 89-90 427-431.
60. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB & Holick MF 2006 The role of vitamin D in cancer prevention. American Journal of Public Health 96 252-261.
61. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ & Budunova IV 2002 The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. Journal of Cell Science 115 141-151.
62. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL et al. 1997 Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50 999-1006.
63. Ghosh S & Karin M 2002 Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl S81-S96.
64. Giaccia A, Siim BG & Johnson RS 2003 HIF-1 as a target for drug development. Nature Reviews. Drug Discovery 2 803-811.
65. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC & Adorini L 2004 A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. Journal of Immunology 173 2280-2287.
66. Giovannucci E 2005 The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes and Control 16 83-95.
67. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N et al. 2009 Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of Internal Medicine 169 141-149.
68. Gleave M & Chi KN 2005 Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Annals of New York Academy of Sciences 1058 1-15.
69. Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R & Olsson CA 1999 Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53 440-445.
70. Gombart AF, Luong QT & Koeffler HP 2006 Vitamin D compounds: activity against microbes and cancer. Anticancer Research 26 2531-2542.
71. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S & Ray WA 2005 Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 475-481.
72. 3 (calcitriol). Journal of Urology 159 2035-2039.
73. Gupta S, Srivastava M, Ahmad N, Bostwick DG & Mukhtar H 2000 Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 73-78.
74. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P & Mukhtar H 2004 Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 64 3334-3343.
75. Hanchette CL & Schwartz GG 1992 Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70 2861-2869.
76. 3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Letters 436 329-334.
77. Hawk ET, Viner JL, Dannenberg A & DuBois RN 2002 COX-2 in cancer - a player that's defining the rules. Journal of the National Cancer Institute 94 545-546.
78. 3-induced growth inhibition. Cancer Research 61 2852-2856.
79. Huang S, Pettaway CA, Uehara H, Bucana CD & Fidler IJ 2001 Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 4188-4197.
80. Hussain T, Gupta S & Mukhtar H 2003 Cyclooxygenase-2 and prostate carcinogenesis. Cancer Letters 191 125-135.
81. Ismail HA, Lessard L, Mes-Masson AM & Saad F 2004 Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 58 308-313.
82. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T&Thun MJ 2008 Cancer statistics, 2008. CA: a Cancer Journal for Clinicians 58 71-96.
83. Jensen SS, Madsen MW, Lukas J, Binderup L & Bartek J 2001 Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Molecular Endocrinology 15 1370-1380.
84. Jogie-Brahim S, Feldman D & Oh Y 2009 Unraveling IGFBP-3 actions in human disease. Endocrine Reviews 30 417-437.
85. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y & Chayama K 2005 Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Research 25 709-713.
86. Kantoff P 2005 Recent progress in management of advanced prostate cancer. Oncology 19 631-636.
87. Karin M & Lin A 2002 NF-kappaB at the crossroads of life and death. Nature Immunology 3 221-227.
88. Kimura K, Bowen C, Spiegel S & Gelmann EP 1999 Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Research 59 1606-1614.
89. 3 and its structural analogs on gene expression in cancer cells - a microarray approach. Anticancer Research 29 3471-3483.
90. Krishnan AV, Peehl DM & Feldman D 2003 Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. Journal of Cellular Biochemistry 88 363-371.
91. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM & Feldman D 2004 Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59 243-251.
92. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM & Feldman D 2007a Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 103 694-702.
93. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM & Feldman D 2007b Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. Journal of Bone and Mineral Research 22 (Suppl 2) V74-V80.
94. Krishnan AV, Srinivas S & Feldman D 2009 Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-Endocrinology 1 1-5.
95. Kundu JK & Surh YJ 2008 Inflammation: gearing the journey to cancer. Mutation Research 659 15-30.
96. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN & Stock RG 2005 C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU International 95 961-962.
97. Lessard L, Begin LR, Gleave ME, Mes-Masson AM & Saad F 2005 Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. British Journal of Cancer 93 1019-1023.
98. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes and Development 10 142-153.
99. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF & Levine AC 2000 Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. Journal of Urology 164 820-825.
100. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF & Levine AC 2002 Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. Journal of Biological Chemistry 277 50081-50086.
101. Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R & Bailey HH 2003 Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clinical Cancer Research 9 4077-4083.
102. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK & Nadler RB 2006 Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 316-320.
103. Lucia MS & Torkko KC 2004 Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. Journal of Urology 171 S30-S34.
104. Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR et al. 2006 Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. Journal of Clinical Investigation 116 892-904.
105. Maeda S & Omata M 2008 Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Science 99 836-842.
106. Maggi M, Crescioli C, Morelli A, Colli E & Adorini L 2006 Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (elocalcitol). Journal of Endocrinological Investigation 29 665-674.
107. 3 is a potent inhibitor of tumor cell-induced angiogenesis. Journal of Investigative Dermatology. Symposium Proceedings 1 97-101.
108. Mantell DJ, Owens PE, Bundred NJ, Mawer EB & Canfield AE 2000 1alpha,25-Dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circulation Research 87 214-220.
109. Mantovani A, Allavena P, Sica A & Balkwill F 2008 Cancer-related inflammation. Nature 454 436-444.
110. Markowitz SD 2007 Aspirin and colon cancer - targeting prevention? New England Journal of Medicine 356 2195-2198.
111. Masuda S & Jones G 2006 Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Molecular Cancer Therapeutics 5 797-808.
112. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA & McMillan DC 2006 Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urologia Internationalis 77 127-129.
113. McCarty MF 2004 Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integrative Cancer Therapies 3 349-380.
114. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk ET, Kelloff G, Lawson MJ, Kidao J, McCracken J et al. 2008 Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prevention Research 1 32-38.
115. Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD & Powell DW 2002 Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. American Journal of Physiology. Cell Physiology 282 C824-C834.
116. Montironi R, Thompson D, Scarpelli M, Mazzucchelli R, Peketi P, Hamilton PW, Bostwick DG & Bartels PH 2004 Karyometry detects subvisual differences in chromatin organization state between cribriform and flat high-grade prostatic intraepithelial neoplasia. Modern Pathology 17 928-937.
117. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM & Feldman D 2005 Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Research 65 7917-7925.
118. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo Get al. 2006 15-Hydroxyprost, taglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.PNAS 103 12098-12102.
119. Narayanan BA, Narayanan NK, Davis L & Nargi D 2006 RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Molecular Cancer Therapeutics 5 1117-1125.
120. Narayanan NK, Nargi D, Horton L, Reddy BS, Bosland MC & Narayanan BA 2009 Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 69 133-141.
121. Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. New England Journal of Medicine 349 366-381.
122. Nelson WG, De Marzo AM, DeWeese TL & Isaacs WB 2004 The role of inflammation in the pathogenesis of prostate cancer. Journal of Urology 172 S6-S11.
123. Nonn L, Peng L, Feldman D & Peehl DM 2006 Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Research 66 4516-4524.
124. Osborne JE & Hutchinson PE 2002 Vitamin D and systemic cancer: is this relevant to malignant melanoma? British Journal of Dermatology 147 197-213.
125. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN & Price BD 1999 Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18 7389-7394.
126. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK & Chi SG 2003 Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22 4314-4332.
127. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. Journal of Steroid Biochemistry 92 131-141.
128. Peng L, Malloy PJ & Feldman D 2004 Identification of a functional Vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Molecular Endocrinology 18 1109-1119.
129. Peng L, Wang J, Malloy PJ & Feldman D 2008 The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. International Journal of Cancer 122 558-566.
130. 3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. Journal of Immunology 178 145-153.
131. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB et al. 2009 The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 69 480-493.
132. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F & Francini G 2007 Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU International 100 775-779.
133. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M et al. 2006 Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute 98 516-521.
134. 3 induces NAD(C)-dependent 15-hydroxyprostaglandin dehydrogenase in human neonatal monocytes. Blood 89 2105-2112.
135. Platz EA, Leitzmann MF, Hollis BW, Willett WC & Giovannucci E 2004 Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes and Control 15 255-265.
136. Rankin EB & Giaccia AJ 2008 The role of hypoxia-inducible factors in tumorigenesis. Cell Death and Differentiation 15 678-685.
137. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG & Griffin MR 2002 COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360 1071-1073.
138. 3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 150 2046-2054.
139. Rose-John S & Schooltink H 2007 Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results in Cancer Research 174 57-66.
140. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S & Llombart-Bosch A 2005 Immunohistochemical expression of Ki-67 antigen, Cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. European Urology 31 31.
141. Sahin M, Sahin E & Gumuslu S 2009 Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60 242-253.
142. Sakamoto S, Ryan AJ & Kyprianou N 2008 Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. Journal of Cellular Biochemistry 103 691-708.
143. Santilli G, Aronow BJ & Sala A 2003 Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. Journal of Biological Chemistry 278 38214-38219.
144. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R et al. 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. Journal of Clinical Oncology 26 1148-1159.
145. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B & Lahm H 2000 Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Letters 151 31-38.
146. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J & Schroder O 2007 Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Molecular Immunology 44 3625-3632.
147. Schwartz GG & Skinner HG 2007 Vitamin D status and cancer: new insights. Current Opinion in Clinical Nutrition and Metabolic Care 10 6-11.
148. 3. Cancer Epidemiology, Biomarkers & Prevention 7 391-395.
149. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clinical Cancer Research 11 8680-8685.
150. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W & Reichrath J 2006 Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation 13 12-19.
151. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Research Treatment 42 31-41.
152. Singer EA, Palapattu GS & van Wijngaarden E 2008 Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 113 2053-2057.
153. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG et al. 2006 Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 1028-1035.
154. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM & Sonenshein GE 1997 Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. Journal of Clinical Investigation 100 2952-2960.
155. Sporn MB & Hong WK 2008 Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prevention Research 1 9-11.
156. Srinivas S & Feldman D 2009 A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Research 29 3605-3610.
157. Stewart LV & Weigel NL 2004 Vitamin D and prostate cancer. Experimental Biology and Medicine 229 277-284.
158. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ & Schroder FH 2007 Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. Journal of Urology 177 107-112.
159. Stio M, Martinesi M, Bruni S, Treves C, Mathieu C, Verstuyf A, d'Albasio G, Bagnoli S & Bonanomi AG 2007 The vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patientswith Crohn's disease. Journal of Steroid Biochemistry and Molecular Biology 103 51-60.
160. Suh J & Rabson AB 2004 NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? Journal of Cellular Biochemistry 91 100-117.
161. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL & Li YC 2006 Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. American Journal of Physiology. Endocrinology and Metabolism 291 E315-E322.
162. 3 decreases human prostate cancer cell adhesion and migration. Molecular and Cellular Endocrinology 164 133-143.
163. Tangpricha V, Pearce EN, Chen TC & Holick MF 2002 Vitamin D insufficiency among free-living healthy young adults. American Journal of Medicine 112 659-662.
164. Tjandrawinata RR & Hughes-Fulford M 1997 Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Advances in Experimental Medicine and Biology 407 163-170.
165. Tjandrawinata RR, Dahiya R & Hughes-Fulford M 1997 Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. British Journal of Cancer 75 1111-1118.
166. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P & Discafani CM 2000 Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine 6 1024-1028.
167. Tretli S, Hernes E, Berg JP, Hestvik UE & Robsahm TE 2009 Association between serum 25(OH)D and death from prostate cancer. British Journal of Cancer 100 450-454.
168. 3) and dexamethasone in androgen-independent prostate cancer. Cancer 106 2136-2142.
169. Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, Hollis BW, Nesline MK, Tian L, Tan W et al. 2009 Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU International 104 909-914.
170. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C & Leto G 2009 Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Medical Oncology 26 10-15.
171. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM & Garzotto M 2005 Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 332 800-807.
172. Wang W, Bergh A & Damber JE 2004 Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61 60-72.
173. Wang W, Bergh A & Damber JE 2005 Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clinical Cancer Research 11 3250-3256.
174. Wang W, Bergh A & Damber JE 2007 Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation. Prostate 67 1238-1246.
175. Wegiel B, Bjartell A, Culig Z & Persson JL 2008 Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. International Journal of Cancer 122 1521-1529.
176. Whittemore AS, Cirillo PM, Feldman D & Cohn BA 2005 Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. Journal of Urology 174 872-876.
177. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY & Koeffler HP 2006 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Research 66 7818-7823.
178. Woo TC, Choo R, Jamieson M, Chander S & Vieth R 2005 Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutrition and Cancer 51 32-36.
179. Wu G, Luo J, Rana JS, Laham R, Sellke FW & Li J 2006 Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovascular Research 69 512-519.
180. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I & St Clair WH 2007 Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Molecular Cancer Therapeutics 6 2048-2056.
181. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK et al. 2004 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. PNAS 101 17468-17473 (epub 2004 Dec 01).
182. Yang ES & Burnstein KL 2003 Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. Journal of Biological Chemistry 278 46862-46868.
183. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T&Wada S 2000 Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 589-596.
184. 3. PNAS 92 10990-10994.
185. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM & Isaacs WB 2001 Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Research 61 8617-8623.
186. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB & De Marzo AM 2004 Cyclooxygenases in cancer: progress and perspective. Cancer Letters 215 1-20.